SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer

NCT04797507 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

33

Enrollment

OTHER

Sponsor class

Conditions

SHR-1210
Anlotinib
Advanced Esophageal Squamous Cell Cancer

Interventions

DRUG: SHR-1210 plus Anlotinib

Sponsor

Peking Union Medical College Hospital